FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940583170> ?p ?o ?g. }

• W2940583170 endingPage "ii97" @default.
• W2940583170 startingPage "ii96" @default.
• W2940583170 abstract "Pediatric brain tumors with replication repair deficiency (RRD) are hypermutant and may respond favorably to immune checkpoint inhibition (ICI). We are collecting ongoing clinical and molecular data from patients with RRD hypermutant cancers treated with ICI as a part of our consortium registry study. Companion biomarkers include tumor mutational burden (TMB), neoantigens and genetic signatures obtained from whole genome and exome sequencing. Immune inference is obtained from RNAseq. Additionally, T-cell receptor rearrangement data are collected from the tumor and blood throughout treatment. From 2015–2018, 53 patients were treated with ICI and combination therapies. Of these 39 had brain tumors, with 93% having high grade gliomas. Two-year overall survival for the entire cohort is 47+/-8%, which compares favorably with historical controls. Tumor location had major impact on outcome. Non-CNS solid tumor patients have 2-year OS of 78+/-11%, all failures occurring within the first 2 months, and sustained responses are observed for 3 years. In contrast, OS for brain tumors is 39+/-10% with late recurrences observed even after 2 years of therapy (p=0.02). Large tumor size and total tumor burden are associated with higher rates of “flare” and poor outcome throughout all cancers. While all tumors are hypermutant, TMB and predicted neoantigens do not correlate with response. However, specific signatures extracted from SNVs and indels are significantly associated with response to ICI and favorable outcome (p=0.005). Notably, RRD IDH1 mutant glioblastomas have particularly poor response to ICI. Interestingly, glioblastomas (n=8) which failed single agent ICI had favorable responses to combination immunotherapies with prolonged survival of 65%+/-8% one year after failure vs 0 for untreated patients (p=0.01). The favorable outcome and responses to ICI are encouraging. Since brain tumors respond less favorably to ICI than other solid tumors, combination therapies based on tumor and immune signatures of these cancers may be beneficial." @default.
• W2940583170 created "2019-05-03" @default.
• W2940583170 creator A5000685371 @default.
• W2940583170 creator A5001024047 @default.
• W2940583170 creator A5001294228 @default.
• W2940583170 creator A5001563606 @default.
• W2940583170 creator A5001673025 @default.
• W2940583170 creator A5002485541 @default.
• W2940583170 creator A5003081774 @default.
• W2940583170 creator A5003397997 @default.
• W2940583170 creator A5005191206 @default.
• W2940583170 creator A5005796905 @default.
• W2940583170 creator A5009137682 @default.
• W2940583170 creator A5010890114 @default.
• W2940583170 creator A5010939758 @default.
• W2940583170 creator A5012891627 @default.
• W2940583170 creator A5013911036 @default.
• W2940583170 creator A5017252824 @default.
• W2940583170 creator A5018138440 @default.
• W2940583170 creator A5019468881 @default.
• W2940583170 creator A5021705500 @default.
• W2940583170 creator A5022310517 @default.
• W2940583170 creator A5023284324 @default.
• W2940583170 creator A5025442855 @default.
• W2940583170 creator A5026737432 @default.
• W2940583170 creator A5026894111 @default.
• W2940583170 creator A5027746254 @default.
• W2940583170 creator A5028980058 @default.
• W2940583170 creator A5029328183 @default.
• W2940583170 creator A5032075563 @default.
• W2940583170 creator A5032789191 @default.
• W2940583170 creator A5033190757 @default.
• W2940583170 creator A5033692158 @default.
• W2940583170 creator A5034350830 @default.
• W2940583170 creator A5039736511 @default.
• W2940583170 creator A5041074495 @default.
• W2940583170 creator A5042455579 @default.
• W2940583170 creator A5043108586 @default.
• W2940583170 creator A5043812430 @default.
• W2940583170 creator A5044016543 @default.
• W2940583170 creator A5046321083 @default.
• W2940583170 creator A5046351275 @default.
• W2940583170 creator A5047012744 @default.
• W2940583170 creator A5047528677 @default.
• W2940583170 creator A5052049681 @default.
• W2940583170 creator A5054237580 @default.
• W2940583170 creator A5055814722 @default.
• W2940583170 creator A5055914007 @default.
• W2940583170 creator A5056512092 @default.
• W2940583170 creator A5058570133 @default.
• W2940583170 creator A5061200396 @default.
• W2940583170 creator A5062426776 @default.
• W2940583170 creator A5063411435 @default.
• W2940583170 creator A5063922230 @default.
• W2940583170 creator A5068257880 @default.
• W2940583170 creator A5068784960 @default.
• W2940583170 creator A5068881416 @default.
• W2940583170 creator A5072241415 @default.
• W2940583170 creator A5073229796 @default.
• W2940583170 creator A5075183737 @default.
• W2940583170 creator A5075401861 @default.
• W2940583170 creator A5076166380 @default.
• W2940583170 creator A5076649152 @default.
• W2940583170 creator A5076835766 @default.
• W2940583170 creator A5078418332 @default.
• W2940583170 creator A5078666991 @default.
• W2940583170 creator A5079656701 @default.
• W2940583170 creator A5080750181 @default.
• W2940583170 creator A5082885008 @default.
• W2940583170 creator A5083509294 @default.
• W2940583170 creator A5084123340 @default.
• W2940583170 creator A5084587717 @default.
• W2940583170 creator A5084930644 @default.
• W2940583170 creator A5088850423 @default.
• W2940583170 creator A5091712536 @default.
• W2940583170 creator A5091756510 @default.
• W2940583170 date "2019-04-01" @default.
• W2940583170 modified "2023-10-13" @default.
• W2940583170 title "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM" @default.
• W2940583170 doi "https://doi.org/10.1093/neuonc/noz036.139" @default.
• W2940583170 hasPublicationYear "2019" @default.
• W2940583170 type Work @default.
• W2940583170 sameAs 2940583170 @default.
• W2940583170 citedByCount "0" @default.
• W2940583170 crossrefType "journal-article" @default.
• W2940583170 hasAuthorship W2940583170A5000685371 @default.
• W2940583170 hasAuthorship W2940583170A5001024047 @default.
• W2940583170 hasAuthorship W2940583170A5001294228 @default.
• W2940583170 hasAuthorship W2940583170A5001563606 @default.
• W2940583170 hasAuthorship W2940583170A5001673025 @default.
• W2940583170 hasAuthorship W2940583170A5002485541 @default.
• W2940583170 hasAuthorship W2940583170A5003081774 @default.
• W2940583170 hasAuthorship W2940583170A5003397997 @default.
• W2940583170 hasAuthorship W2940583170A5005191206 @default.
• W2940583170 hasAuthorship W2940583170A5005796905 @default.
• W2940583170 hasAuthorship W2940583170A5009137682 @default.
• W2940583170 hasAuthorship W2940583170A5010890114 @default.
• W2940583170 hasAuthorship W2940583170A5010939758 @default.

• next